Close Menu

NuProbe VarMap Panels

Apr 22, 2020

Houston-based sample preparation firm NuProbe has launched its VarMap targeted next-generation sequencing product line. NuProbe's first target enrichment assays include multi-gene panels for non-small cell lung cancer and melanoma. They require 500x sequencing depth to detect and quantitate tumor-specific mutations at 0.1 percent variant allele frequency. The assays allow for detection of low-abundance tumor-specific mutations to help with therapy selection and minimal residual disease monitoring, the company said.

More Like This

Jul 07, 2020

Horizon Discovery Cas9, dCas9-VPR Cell Lines

Horizon Discovery has released its stably expressing Cas9 and dCas9-VPR cell lines to aid researchers in gene knockout and gene activation experiments, respectively. The cell lines are optimized to work alongside Horizon's Edit-R predesigned synthetic single-guide RNA and CRISPRa guide RNA, for complete, simple, and streamlined CRISPR gene editing and modulation workflows.

The Cas9 and dCas9-VPR stable cell lines were generated using Horizon's Edit-R Lentiviral particles with a blasticidin resistance cassette, and are provided in pooled format. The cell lines are QC verified and validated to ensure stable expression and functionality of Cas9 or dCas9-VPR endonuclease in a range of common cell backgrounds, the company said. Both cell lines are available in the same background to enable loss- and gain-of-function studies to be performed in parallel. 

Jul 01, 2020

Myriad Genetics Home Sample Collection Kit for GeneSight Psychotropic

Myriad Genetics has launched an at-home sample collection kit for its pharmacogenetic test GeneSight Psychotropic. The DNA sample for this test is typically collected in a physician's office, but the new kit will allow patients to use a swab to collect a sample from inside their cheeks and mail it to the Myriad Neuroscience CLIA-certified and CAP-accredited lab for analysis. Even though the new kit allows home sample collection, the test must be ordered by a licensed healthcare provider.

Mark Verratti, president of Myriad Neuroscience, said in a statement that during the COVID-19 pandemic there has been a rise in patients experiencing depression and anxiety, while at the same time more physicians are practicing telemedicine to limit patients' exposures to the virus. Verratti added that the new collection kit allows clinicians to continue to use the GeneSight test as part of developing a treatment plan for their patients suffering from depression or anxiety.

Jun 30, 2020

Twist Bioscience Respiratory Virus Research Panel

Twist Bioscience has launched the Twist Respiratory Virus Research Panel, a next-generation sequencing approach to detecting 29 common human respiratory viruses including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses, and respiratory syncytial virus. The research-use-only panel will be bundled with an analysis platform from One Codex to enable a complete workflow beginning with Twist's target enrichment panel and ending with publication-ready visuals, the company said. The panel includes RNA- and DNA-based viruses in one kit with 41,047 nucleic acid probes, can detect as little as 100 copies of viral material, and has coverage of greater than 99.9 percent of the genome at 1X or greater post-enrichment.

Jun 30, 2020

Flagship Biosciences TissueInsight

Flagship Biosciences has launched a new clinical diagnostics immuno-oncology service called TissueInsight, which provides CLIA-reportable PD-L1 results along with data about a tumor's microenvironment to pathologists, oncologists, and immunologists to aid them in optimizing care for cancer patients. According to the company, users of the service follow their normal IHC slide staining process, then scan the slides and send the images to Flagship, which analyzes them with their proprietary image-analysis process. TissueInsight gives rapid, data-rich tissue interpretation and removes the inherent variability of subjective manual tissue scoring, the company said. Along with its CLIA-reportable results, TissueInsight tumor microenvironment data includes information on tumor infiltrating lymphocytes and macrophages, the company added.

Jun 29, 2020

GenMark Diagnostics ePlex Respiratory Pathogen Panel 2

GenMark Diagnostics said its ePlex Respiratory Pathogen 2 (RP2) Panel is now available for US commercial distribution and clinical use. The panel is designed to provide results in less than two hours for SARS-CoV-2 and other common respiratory pathogens, including influenza, adenovirus, rhinovirus, and respiratory syncytial virus (RSV). 

GenMark said that earlier this month, it had applied to the US Food and Drug Administration for Emergency Use Authorization of its ePlex Respiratory Pathogen 2 Panel. In March, the company received EUA for its ePlex SARS-CoV-2 Test.

Jun 29, 2020

NeoGenomics Liquid Biopsy Assays

NeoGenomics announced the launch of three new liquid biopsy products for advanced non-small cell lung cancer, all solid tumor types, and breast cancer.

The InVisionFirst-Lung liquid biopsy assay tests 37 genes related to the care of advanced NSCLC and covers all National Comprehensive Cancer Network guideline-recommended genomic drivers with targeted therapies for NSCLC. NeoGenomics partnered with Inivata to commercialize the test. 

The NeoLab Solid Tumor Liquid Biopsy is a next-generation sequencing test for genomic profiling of solid tumors. The test is part of the NeoLab suite of assays providing biomarker evaluation for patients with hematologic diseases who can't have a bone marrow biopsy and whose peripheral blood counts are low. 

The Qiagen Therascreen PIK3CA RGQ PCR kit is a companion diagnostic approved by the US Food and Drug Administration for use with alpelisib (Novartis' Piqray) that detects 11 clinically actionable mutations in the PIK3CA gene. NeoGenomics will launch the test in situations where PIK3CA testing can't be performed using tumor tissue due to insufficient samples, low quantities of tumor cells, or tissue sample decalcification. 

Jun 26, 2020

Oxford Nanopore Technologies Q Line

Oxford Nanopore Technologies has launched a number of nanopore sequencing products, called Q Line, for diagnostics and other regulated markets. The Q Line products are ISO9001-qualified and allow for sequencing in a locked-down, standardized format. They are designed for water testing, veterinary diagnostics, pharmaceutical research, industrial diagnostics, forensics, and clinical research applications. The first Q Line product is the GridIon Q, a locked-down version of the GridIon sequencer with an integrated compute system. It will be available with two kits, Ligation Sequencing Kit Q and Native Barcoding Expansion Q. More Q Line products will follow, including a MinIon MK1C Q, a Flongle Q, and additional kits.

Jun 25, 2020

Guardant Health GuardantInform

Guardant Health has launched a clinical-genomic database service it calls GuardantInform, intended to help accelerate research and development of the next generation of cancer therapeutics. The platform offers biopharma partners de-identified longitudinal clinical information and genomic data collected from the Guardant360 liquid biopsy test, which the firm has performed on more than 100,000 samples to date.

Among potential applications, Guardant highlighted targeted drug development, clinical trial optimization, and post-marketing pharma studies. According to the company, recent data presented at the AACR virtual annual meeting further support the database's potential in these areas.

Jun 23, 2020

LGC Maine Standards Validate ACTH Linearity and Calibration Verification Test Kits

LGC Maine Standards has released the Validate ACTH Linearity and Calibration Verification Test Kits to document linearity, for calibration verification, and for analytical measurement range verification of Adrenocorticotropic Hormone. The product provides five concentrations across the Elecsys-ATCH method on Roche's Cobas instrument and is formulated in a human plasma matrix. 

The product helps minimize manual dilutions and fulfills various quality control requirements, strengthening LGC's product range for endocrine testing, which includes 17 analytes. 

Jun 23, 2020

IDT gBlocks HiFi Gene Fragments

Integrated DNA Technologies has launched gBlocks HiFi Gene Fragments, double-stranded DNA fragments between 1,000 and 3,000 bp in length.

The fragments have an error rate of less than 1 in 12,000 bp and are verified with next-generation sequencing. Turnaround time is between six and 10 business days.

Applications include synthetic biology, pathway development, traditional cloning, and large construct assembly.

Jun 23, 2020

Seven Bridges Graf Genome Analysis

Bioinformatics firm Seven Bridges has made its graph-based genome analysis methods for population genomics available. The offering replaces the previous Graph Genome Suite.

Moreover, the company is offering its Graf Germline Variant Detection workflow and Pan Genome Reference to academic researchers for free.

Graf tools offer the ability to create population-specific genome graphs, curated genome graphs for rare disease, bespoke and family genome graphs for de novo mutation detection, and cancer and normal sample genome graphs for detecting somatic mutations in tumors.  

The tools improve genome analysis for people with non-European heritage, support more diverse population studies, and provide more accurate insertion and deletion calls.

Jun 23, 2020

Genedata Selector 6.0

Genedata has released its Selector 6.0 enterprise software for biopharmaceutical R&D. This newest version of Selector automates next-generation sequencing-based workflows with wizard-style playbooks that guide users through the entire workflow from sample registration to report generation, Genedata said. The workflows can be approved and locked for use in playbooks to minimize the risk of variations in data processing. Other new features include a configurable dashboard with status cards to provide scientists and managers quick access to project status and other information and a robust genome loading tool that enhances system performance and simplifies genome database maintenance, Genedata said.

Jun 19, 2020

HTG Molecular EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics has pre-launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel, which the firm expects to offer as a kit or as a service for research use only use starting in July. The panel is designed to provide molecular characterization of aggressive lymphomas by allowing researchers to measure the expression of genes linked to the aggressive lymphoma transcriptome. The panel is an extension of HTG's DLBCL assay. 

Jun 19, 2020

NanoString COVID-19 Disease Research Products

NanoString Technologies has launched a set of new solutions for studying immune response in COVID-19 disease research, which include the Host Response Gene Expression Panel and COVID -19 Panel Plus spike-in, as well as new protein and RNA content available on the GeoMx Digital Spatial Profiler.

The COVID-19 GeoMx-formatted Antibody Panel, from Abcam, provides a customizable panel which will be run with the GeoMx Immune Profiling Core to enable spatial analysis of 96 proteins involved in the immune response to SARS-CoV-2 infection. It is currently available through NanoString's GeoMx technology access program. The Host Response assay includes 770 genes focused on host susceptibility, interferon signaling, innate and adaptive immunity as well as other key areas of biology to characterize host response to infection. The COVID-19 panel contains probes targeting all SARS-CoV-2 genes as well as the host ACE receptor that is bound by the virus. 

Jun 19, 2020

LGC SeraCare AccuSet SARS-CoV-2 Performance Panel

LGC SeraCare has released the AccuSet SARS-CoV-2 Performance Panel, an eleven-member validation panel of undiluted, naturally occurring human plasma samples. Ten panel samples represent collections from multiple individuals positive for antibodies to SARS-CoV-2; a single negative sample is also included, according to the company's website. The panel is designed to support validation studies for SARS-CoV-2 diagnostic developers and to help meet assay verification requirements in clinical laboratories.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

Jul
09
Sponsored by
Illumina

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
22
Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).